Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Inflammatory Bowel Diseases

Free Subscription Articles published in Eur J Gastroenterol Hepatol Retrieve available abstracts of 150 articles: HTML format

Single Articles

December 2023
1. SONNENBERG A, Duong HT, McCarty DJ, El-Serag HB, et al
   Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma.
   Eur J Gastroenterol Hepatol. 2023;35:1349-1353.
   PubMed     Abstract available
   
   
   
2. STJARNGRIM J, Ekbom A, Widman L, Hultcrantz R, et al
   Post-colonoscopy rectal cancer in Swedish patients with Crohn's disease 2001-2015: a population-based case review study.
   Eur J Gastroenterol Hepatol. 2023;35:1334-1340.
   PubMed     Abstract available
   
   
   November 2023
3. NGUYEN AL, Herath M, Burns M, Holt D, et al
   The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study.
   Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002675.
   PubMed     Abstract available
   
   
   October 2023
4. LIU C, Liu X, Shi H, Chen F, et al
   The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis.
   Eur J Gastroenterol Hepatol. 2023 Oct 18. doi: 10.1097/MEG.0000000000002670.
   PubMed     Abstract available
   
   
   
5. BARAUNA FSB, Magro DO, Miranda EF, Marcal GN, et al
   Correlation between trough levels of infliximab and postoperative endoscopic recurrence in Crohn's disease patients submitted to ileocolonic resections.
   Eur J Gastroenterol Hepatol. 2023 Oct 6. doi: 10.1097/MEG.0000000000002639.
   PubMed     Abstract available
   
   
   
6. VALIBOUZE C, Nachury M, Hambli S, Desreumaux P, et al
   Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitis.
   Eur J Gastroenterol Hepatol. 2023;35:1230.
   PubMed    
   
   
   
7. JANSEN FM, den Broeder N, Lubeek SFK, Savelkoul EHJ, et al
   Cumulative thiopurine dosing and keratinocyte skin cancer in inflammatory bowel disease: a case-control study.
   Eur J Gastroenterol Hepatol. 2023;35:1123-1130.
   PubMed     Abstract available
   
   
   September 2023
8. FERRARO S, Cappello E, Bartolini C, Convertino I, et al
   Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
   Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002642.
   PubMed     Abstract available
   
   
   
9. ALHALABI M, Alaa Eddin K, Abbas A
   Therapeutic effects of biological treatments on AA amyloidosis associated with inflammatory bowel disease: a case report and literature review.
   Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002649.
   PubMed     Abstract available
   
   
   
10. HONAP S, Irving PM, Samaan MA
    JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002650.
    PubMed     Abstract available
    
    
    
11. NERI B, D'Agostini G, Salvatori S, Mossa M, et al
    Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
    Eur J Gastroenterol Hepatol. 2023;35:948-954.
    PubMed     Abstract available
    
    
    August 2023
12. ZHANG T, Zhang QD, Jin T, Li WJ, et al
    Is histological healing more clinically valuable than endoscopic healing in Crohn's disease?
    Eur J Gastroenterol Hepatol. 2023 Aug 14. doi: 10.1097/MEG.0000000000002624.
    PubMed     Abstract available
    
    
    
13. TSAFARIDOU M, Augoustaki A, Koutroubakis I
    Lymphogranuloma venereum and CMV co-infection mimicking ulcerative proctitis in a non-immunocompromised patient.
    Eur J Gastroenterol Hepatol. 2023;35:921-922.
    PubMed    
    
    
    
14. HUANG Y, Su Y, Qin R, Wang L, et al
    Mechanism by which oleracein E alleviates TNBS-induced ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:854-864.
    PubMed     Abstract available
    
    
    July 2023
15. LYKOWSKA-SZUBER L, Walczak M, Dobrowolska A, Skrzypczak-Zielinska M, et al
    Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002618.
    PubMed     Abstract available
    
    
    
16. ZHAN Y, Cheng X, Mei P, Wu J, et al
    Risk and incidence of colorectal stricture progressing to colorectal neoplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002614.
    PubMed     Abstract available
    
    
    
17. BOUSTANY A, Rahhal R, Mitri J, Onwuzo S, et al
    The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
    Eur J Gastroenterol Hepatol. 2023 Jul 11. doi: 10.1097/MEG.0000000000002607.
    PubMed     Abstract available
    
    
    May 2023
18. KONSTANTINOU CS, Korantzopoulos P, Fousekis FS, Katsanos KH, et al
    Inflammatory bowel disease and atrial fibrillation: a contemporary overview.
    Eur J Gastroenterol Hepatol. 2023 May 8. doi: 10.1097/MEG.0000000000002562.
    PubMed     Abstract available
    
    
    
19. HASSAN EA, Abdel Rehim ASE, Ahmed AO, Salim SMAE, et al
    Current insight into enteropathogens in flare-up ulcerative colitis. An observational study.
    Eur J Gastroenterol Hepatol. 2023 May 3. doi: 10.1097/MEG.0000000000002563.
    PubMed     Abstract available
    
    
    
20. PRENTICE RE, Wright EK, Flanagan E, Kamm MA, et al
    Evaluation and management of ileal pouch-anal anastamosis (IPAA) complications in pregnancy, and the impacts of an IPAA on fertility.
    Eur J Gastroenterol Hepatol. 2023;35:609-612.
    PubMed     Abstract available
    
    
    April 2023
21. CHAHAL JK, Sriranganathan D, Poo S, Lo SW, et al
    Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's disease.
    Eur J Gastroenterol Hepatol. 2023 Apr 11. doi: 10.1097/MEG.0000000000002552.
    PubMed     Abstract available
    
    
    
22. PRINCIPI M, Macaluso FS, Todeschini A, Facciotti F, et al
    Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD).
    Eur J Gastroenterol Hepatol. 2023 Apr 4. doi: 10.1097/MEG.0000000000002550.
    PubMed     Abstract available
    
    
    
23. FARIA LM, Oliveira MM, Faria AA, Vasconcellos AVO, et al
    Late onset vedolizumab-induced eosinophilic pneumonia in a patient with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:513-514.
    PubMed    
    
    
    
24. KOKKOTIS G, Zampeli E, Tzouvala M, Giotis I, et al
    Prevalence and predictors of arthralgia after initiation of vedolizumab in patients with inflammatory bowel disease: a retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2023;35:371-375.
    PubMed     Abstract available
    
    
    March 2023
25. NOVAK G, Sever N, Hanzel J, Kozelj M, et al
    Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023 Mar 20. doi: 10.1097/MEG.0000000000002543.
    PubMed     Abstract available
    
    
    
26. STJARNGRIM J, Widman L, Schmidt PT, Ekbom A, et al
    Post-endoscopy colorectal cancer after colectomy in inflammatory bowel disease patients: a population-based register study.
    Eur J Gastroenterol Hepatol. 2023;35:288-293.
    PubMed     Abstract available
    
    
    
27. XUE M, Chen J, Zheng W, Liu Y, et al
    Clinical characteristics and quality of life in patients with inflammatory bowel disease-associated anemia in Southeast China.
    Eur J Gastroenterol Hepatol. 2023;35:275-284.
    PubMed     Abstract available
    
    
    
28. SAYED A, Assis DN, Silveira MG, Deng Y, et al
    Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2023;35:270-274.
    PubMed     Abstract available
    
    
    
29. THOMAS PWA, van Caem M, West RL, Russel MGVM, et al
    Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
    Eur J Gastroenterol Hepatol. 2023;35:261-269.
    PubMed     Abstract available
    
    
    
30. LOOSEN SH, Kostev K, Scholer D, Orth HM, et al
    Infectious mononucleosis is associated with an increased incidence of Crohn's disease: results from a cohort study of 31 862 outpatients in Germany.
    Eur J Gastroenterol Hepatol. 2023;35:255-260.
    PubMed     Abstract available
    
    
    
31. TANDON P, Natt N, Malhi G, Wong EC, et al
    Clinical remission in paired phase two and three studies in inflammatory bowel disease: a systematic review with meta-analysis.
    Eur J Gastroenterol Hepatol. 2023;35:231-240.
    PubMed     Abstract available
    
    
    February 2023
32. SCALVINI D, Schiepatti A, Maimaris S, Cosentini E, et al
    Humoral immunogenicity of COVID-19 vaccines in patients with coeliac disease and other noncoeliac enteropathies compared to healthy controls.
    Eur J Gastroenterol Hepatol. 2023;35:167-173.
    PubMed     Abstract available
    
    
    January 2023
33. TEN BOKKEL HUININK S, Beelen EMJ, Ten Bokkel Huinink T, Hoentjen F, et al
    Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy.
    Eur J Gastroenterol Hepatol. 2023;35:45-51.
    PubMed     Abstract available
    
    
    December 2022
34. FOUSEKIS FS, Katsanos KH, Popovic DD
    Translation and validation of questionnaires: necessary processes for inflammatory bowel disease studies reliability.
    Eur J Gastroenterol Hepatol. 2022;34:1201-1202.
    PubMed    
    
    
    
35. NARULA N, Wong ECL, Moayyedi P, Reinisch W, et al
    Pilot study of an elimination diet in adults with mild to moderate Crohn's disease.
    Eur J Gastroenterol Hepatol. 2022;34:1210-1219.
    PubMed     Abstract available
    
    
    November 2022
36. FISKE J, Liu E, Limdi JK, Conley TE, et al
    Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2022;34:1132-1139.
    PubMed     Abstract available
    
    
    
37. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:1125-1131.
    PubMed     Abstract available
    
    
    October 2022
38. MARTINHO-GRUEBER M, Kapoglou I, Bravo F, Sarraj R, et al
    Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease.
    Eur J Gastroenterol Hepatol. 2022 Oct 26. pii: 00042737-990000000-00082.
    PubMed     Abstract available
    
    
    
39. MOENS A, Alsoud D, Verstockt B, Sabino J, et al
    Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Eur J Gastroenterol Hepatol. 2022;34:1015-1020.
    PubMed     Abstract available
    
    
    
40. TEN BOKKEL HUININK S, de Jong DC, Nieboer D, Thomassen D, et al
    Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2022;34:983-992.
    PubMed     Abstract available
    
    
    September 2022
41. CASSINOTTI A, Mezzina N, De Silvestri A, Di Paolo D, et al
    Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study.
    Eur J Gastroenterol Hepatol. 2022 Sep 23. pii: 00042737-990000000-00076.
    PubMed     Abstract available
    
    
    
42. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00059.
    PubMed     Abstract available
    
    
    
43. THEODORAKI E, Orfanoudaki E, Petroulaki E, Foteinogiannopoulou K, et al
    Active smoking is associated with the development of adverse events of biological therapy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00073.
    PubMed     Abstract available
    
    
    
44. PAUPARD T, Gonzalez F, Caron B, Siproudhis L, et al
    Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00067.
    PubMed     Abstract available
    
    
    
45. ROBERTS CM, Gamwell KL, Baudino MN, Edwards CS, et al
    Illness stigma, body image dissatisfaction, thwarted belongingness and depressive symptoms in youth with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:919-924.
    PubMed     Abstract available
    
    
    August 2022
46. TURSI A, Lopetuso LR, Vetrone LM, Gasbarrini A, et al
    SARS-CoV-2 infection as a potential trigger factor for de novo occurrence of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:883-884.
    PubMed    
    
    
    
47. WEWER MD, Karstensen JG, Burisch J
    Endoscopic small bowel balloon dilations in patients with Crohn's disease: a Danish nationwide cohort study, 1997-2015.
    Eur J Gastroenterol Hepatol. 2022;34:831-837.
    PubMed     Abstract available
    
    
    July 2022
48. ZHU F, Qin Y, Wang Y, Zhang F, et al
    Critical roles of RGS16 in the mucosal inflammation of ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2022 Jul 14. pii: 00042737-990000000-00034.
    PubMed     Abstract available
    
    
    
49. DIPASQUALE V, Pellegrino S, Ventimiglia M, Cucinotta U, et al
    Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.
    Eur J Gastroenterol Hepatol. 2022 Jul 14. pii: 00042737-990000000-00036.
    PubMed     Abstract available
    
    
    
50. GIRI S, Ingawale S
    Use of restrictive iron transfusion strategy in inflammatory bowel disease: one size does not fit all.
    Eur J Gastroenterol Hepatol. 2022;34:807.
    PubMed    
    
    
    
51. GROVA M, Crispino F, Maida M, Macaluso FS, et al
    Authors' reply to 'Use of restrictive iron transfusion strategy in IBD: one size does not fit all'.
    Eur J Gastroenterol Hepatol. 2022;34:808.
    PubMed    
    
    
    April 2022
52. FERRANTE M, Schirbel A, Pierik MJ, Haas T, et al
    Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
    Eur J Gastroenterol Hepatol. 2022 Apr 8. pii: 00042737-990000000-00016.
    PubMed     Abstract available
    
    
    
53. GOMOLLON F, Gisbert JP, Guerra I, Plaza R, et al
    Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study.
    Eur J Gastroenterol Hepatol. 2022;34:389-397.
    PubMed     Abstract available
    
    
    
54. BODINI G, Demarzo MG, Djahandideh A, Ziola S, et al
    Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques.
    Eur J Gastroenterol Hepatol. 2022;34:382-388.
    PubMed     Abstract available
    
    
    
55. HOWARD G, Weiner D, Bar-Or I, Levine A, et al
    Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children.
    Eur J Gastroenterol Hepatol. 2022;34:372-374.
    PubMed     Abstract available
    
    
    March 2022
56. SMITH RL, Taylor KM, Friedman AB, Gibson DJ, et al
    Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00008.
    PubMed     Abstract available
    
    
    
57. CHUCK W, Shadbolt BF, Nordin F, Subramaniam K, et al
    BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-alpha inhibitors.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00002.
    PubMed     Abstract available
    
    
    
58. YOSHIDA A, Kimura K, Morizane T, Ueno F, et al
    Predictor of primary response to antitumor necrosis factor-alpha therapy for inflammatory bowel disease: a single-center observational study.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00007.
    PubMed     Abstract available
    
    
    
59. LEI N, Kong P, Chen S, Wang Q, et al
    Upregulated NORAD is implicated in apoptosis, inflammation, and oxidative stress in ulcerative colitis through the nuclear factor-kappaappaB signaling.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00004.
    PubMed     Abstract available
    
    
    
60. POO S, Sriranganathan D, Segal JP
    Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2022 Mar 9. pii: 00042737-900000000-97083.
    PubMed     Abstract available
    
    
    
61. DAWRA S, Manrai M, Kumar A, Kumar S, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systemic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2022;34:359-360.
    PubMed    
    
    
    
62. TUN GSZ, Robinson K, Marshall L, Wright A, et al
    The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab.
    Eur J Gastroenterol Hepatol. 2022;34:295-301.
    PubMed     Abstract available
    
    
    February 2022
63. FALLING CL, Stebbings S, David Baxter G, Siegel CA, et al
    Somatosensory assessments in patients with inflammatory bowel disease: a cross-sectional study examining pain processing pathways and the role of multiple patient factors.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97087.
    PubMed     Abstract available
    
    
    January 2022
64. GROVA M, Crispino F, Maida M, Renna S, et al
    Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97093.
    PubMed     Abstract available
    
    
    
65. GIANNOS P, Triantafyllidis KK, Giannos G, Kechagias KS, et al
    SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97092.
    PubMed     Abstract available
    
    
    
66. KRUIS W, Leifeld L
    Response to: Malignancy associated to perianal Chrohn s fistula - a challenge for more clinical research.
    Eur J Gastroenterol Hepatol. 2022;34:9-10.
    PubMed    
    
    
    
67. ADEGBOLA SO, Sarafian M, Sahnan K, Pechlivanis A, et al
    Lack of anti-TNF drugs levels in fistula tissue - a reason for nonresponse in Crohn's perianal fistulating disease?
    Eur J Gastroenterol Hepatol. 2022;34:18-26.
    PubMed     Abstract available
    
    
    December 2021
68. THOMAS PWA, Smits LJT, Te Groen M, West RL, et al
    De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97101.
    PubMed     Abstract available
    
    
    
69. GUILLO L, Bonnaud G, Nahon S, Caron B, et al
    French experience with telemedicine in inflammatory bowel disease: a patients and physicians survey.
    Eur J Gastroenterol Hepatol. 2021 Dec 3. pii: 00042737-900000000-97115.
    PubMed     Abstract available
    
    
    
70. GOODDAY SM, Travis S, Walsh A, Friend SH, et al
    Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33:1511-1516.
    PubMed     Abstract available
    
    
    
71. ADEGBOLA SO, Sarafian M, Sahnan K, Ding NS, et al
    Differences in amino acid and lipid metabolism distinguish Crohn's from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis.
    Eur J Gastroenterol Hepatol. 2021;33:1469-1479.
    PubMed     Abstract available
    
    
    
72. SINGH AK, Kumar-M P, Sharma V
    Hyperbaric oxygen therapy for ulcerative colitis: conflicting evidence from randomized trials.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
73. TURSI A
    Performances of anti-TNFalpha antibodies as long-term maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
74. MOURAD FH, Leong RW, Kariyawasam VC
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
75. NG A
    Mind the lipids: hyperlipidaemia resultant from JAK inhibitor use in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
76. NG A
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
77. NG A
    The efficacy of tumour necrosis factor-alpha antagonists in maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
78. GARRIDO I, Santos AL, Lopes J, Lopes S, et al
    "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug".
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
79. DING NS, Lee T, Bettenworth D, Cleynen I, et al
    Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
80. INNOCENTI T, Roselli J, Lynch EN, Apolito P, et al
    Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
81. VIOLA A, Muscianisi M, Voti RL, Costantino G, et al
    Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
82. HILARY K, Carthage M, Jawad R, Karen B, et al
    Lost in words? The readability of medication information sheets in commonly used medication in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
83. NG A
    Histological subtypes of perianal fistula-associated malignancies in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
84. SILVA MENDES S, Ferreira P, Antunes P, Goncalves M, et al
    Validation of the IBD-Disk in a Portuguese cohort.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
85. LI X, Wang Y, Ge T, Xiao Y, et al
    Henoch-Schonlein purpura associated with infliximab therapy for pediatric Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
86. HANZEL J, Kozelj M, Spes Hlastec A, Kurent T, et al
    Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
87. TEN BOKKEL HUININK S, Biemans V, Duijvestein M, Pierik M, et al
    Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
88. PIAZZOLLA M, Marmo R, Terracciano F, Perri F, et al
    Asymptomatic retention of fragmented small bowel capsule endoscopy retrieved by retrograde double-balloon enteroscopy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
89. SALVATORI S, Marafini I, Monteleone G
    Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
90. LI T, Gao L, Cao L, Guo Z, et al
    Changes in disease behaviour and location and factor analysis in patients with Crohn's disease undergoing repeated-resections.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
91. CROCETTI E, Bergamaschi W, Russo AG
    Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
92. WALSHE M, Borowski K, Boland K, Rho S, et al
    Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    November 2021
93. YAO J, Gao R, Luo M, Li D, et al
    Long noncoding RNA KIF9-AS1 promotes cell apoptosis by targeting the microRNA-148a-3p/suppressor of cytokine signaling axis in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Nov 8. pii: 00042737-900000000-97127.
    PubMed     Abstract available
    
    
    
94. TURSI A, Florio T, Tiano M
    Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab.
    Eur J Gastroenterol Hepatol. 2021;33:1462-1464.
    PubMed    
    
    
    
95. PUTIGNANI L, Oliva S, Isoldi S, Del Chierico F, et al
    Fecal and mucosal microbiota profiling in pediatric inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33:1376-1386.
    PubMed     Abstract available
    
    
    October 2021
96. SHAMSEYA AM, Hussein WM, Elnely DA, Adel F, et al
    Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Oct 20. pii: 00042737-900000000-97135.
    PubMed     Abstract available
    
    
    
97. VELAYOS JIMENEZ B, Del Olmo Martinez L, Macho Conesa A, Fernandez Salazar L, et al
    Should the birth month be considered as one of the possible environmental risk factors in the pathogenesis of inflammatory bowel disease?
    Eur J Gastroenterol Hepatol. 2021;33:1332.
    PubMed    
    
    
    
98. GREENER T, Boland K, Milgrom R, Ben-Bassat O, et al
    Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2021;33:1274-1279.
    PubMed     Abstract available
    
    
    August 2021
99. BAMIAS G, Kokkotis G, Christidou A, Christodoulou DK, et al
    The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD.
    Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97160.
    PubMed     Abstract available
    
    
    
100. KARIMI N, Sechi AJ, Harb M, Sawyer E, et al
     The effect of a nurse-led advice line and virtual clinic on inflammatory bowel disease service delivery: an Australian study.
     Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97158.
     PubMed     Abstract available
     
     
     
101. CAPRIOLI F, Daperno M, Bravata I, Brigido A, et al
     Who are the patients with Crohn's disease unsuitable to receive an anti-TNFalpha therapy? Results from a survey of Italian physicians and literature review.
     Eur J Gastroenterol Hepatol. 2021;33:1082-1090.
     PubMed     Abstract available
     
     
     
102. GONG W, Guo K, Zheng T, Xie H, et al
     JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease.
     Eur J Gastroenterol Hepatol. 2021;33:1049-1054.
     PubMed     Abstract available
     
     
     July 2021
103. SMITH RL, Taylor KM, Friedman AB, Su HY, et al
     Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97173.
     PubMed     Abstract available
     
     
     
104. GONZALEZ-PARTIDA I, Martinez-Lozano H, Gonzalez-Lois C, Peligros I, et al
     Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing.
     Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97168.
     PubMed     Abstract available
     
     
     
105. ORFANOUDAKI E, Drygiannakis I, Theodoraki E, Foteinogiannopoulou K, et al
     Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab.
     Eur J Gastroenterol Hepatol. 2021 Jul 19. pii: 00042737-900000000-97178.
     PubMed     Abstract available
     
     
     
106. CORTEGOSO VALDIVIA P, Elosua A, Houdeville C, Pennazio M, et al
     Clinical feasibility of panintestinal (or panenteric) capsule endoscopy: a systematic review.
     Eur J Gastroenterol Hepatol. 2021;33:949-955.
     PubMed     Abstract available
     
     
     
107. NERI B, Scarozza P, Giannarelli D, Sena G, et al
     Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases.
     Eur J Gastroenterol Hepatol. 2021;33:977-982.
     PubMed     Abstract available
     
     
     
108. LIVNE M, Amitai MM, Klang E, Ben Horin S, et al
     Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score.
     Eur J Gastroenterol Hepatol. 2021;33:961-966.
     PubMed     Abstract available
     
     
     June 2021
109. RICHTER V, Bermont A, Cohen DL, Broide E, et al
     Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
     Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97186.
     PubMed     Abstract available
     
     
     
110. ATTAUABI M, Vind I, Pedersen G, Bendtsen F, et al
     Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study.
     Eur J Gastroenterol Hepatol. 2021 Jun 7. pii: 00042737-900000000-97194.
     PubMed     Abstract available
     
     
     
111. LLAO J, Masnou H, Romero C, Bargallo A, et al
     Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate.
     Eur J Gastroenterol Hepatol. 2021;33:794-798.
     PubMed     Abstract available
     
     
     May 2021
112. RIZOS ED, Antonogiannaki EM, Chatzidakis A, Kallieri M, et al
     Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97199.
     PubMed     Abstract available
     
     
     
113. GATOPOULOU A, Christodoulou DK, Katsanos KH, Bakos D, et al
     Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Gree
     Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97217.
     PubMed     Abstract available
     
     
     
114. VOHRA I, Attar B, Haghbin H, Mutneja H, et al
     Incidence and risk factors for 30-day readmission in ulcerative colitis: nationwide analysis in biologic era.
     Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97210.
     PubMed     Abstract available
     
     
     
115. ANGELINO G, Cifaldi C, Zangari P, Di Cesare S, et al
     Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
     Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97208.
     PubMed     Abstract available
     
     
     
116. VAN GENNEP S, Gielen ME, Rietdijk ST, de Boer NKH, et al
     Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study.
     Eur J Gastroenterol Hepatol. 2021 May 3. doi: 10.1097/MEG.0000000000002178.
     PubMed     Abstract available
     
     
     
117. VIGLIO A, Lenti MV, Vanoli A, Di Sabatino A, et al
     Rectal neuroendocrine cell proliferation in a patient with ulcerative colitis treated with adalimumab.
     Eur J Gastroenterol Hepatol. 2021;33:766-768.
     PubMed    
     
     
     
118. TURSI A, Mocci G, Lorenzetti R, Allegretta L, et al
     Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
     Eur J Gastroenterol Hepatol. 2021;33:670-679.
     PubMed     Abstract available
     
     
     
119. FREITAS M, Curdia Goncalves T, Boal Carvalho P, Dias de Castro F, et al
     From terminal ileitis to Crohn's disease: how capsule endoscopy is crucial to diagnosis.
     Eur J Gastroenterol Hepatol. 2021;33:631-638.
     PubMed     Abstract available
     
     
     April 2021
120. SINGH AK, Jha DK, Jena A, Kumar-M P, et al
     Hyperbaric oxygen therapy in inflammatory bowel disease: a systematic review and meta-analysis.
     Eur J Gastroenterol Hepatol. 2021 Apr 19. doi: 10.1097/MEG.0000000000002164.
     PubMed     Abstract available
     
     
     
121. CORREIA JP, Ponte AI, Silva JC, Gomes AC, et al
     Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2021;33:595.
     PubMed    
     
     
     
122. GONELLA F, Massucco P, Daperno M, Mineccia M, et al
     Ulcerative enteritis. How the extension of ulcerative colitis to small bowel may jeopardize postcolectomy course: a case report and literature review.
     Eur J Gastroenterol Hepatol. 2021;33:589-594.
     PubMed     Abstract available
     
     
     
123. GOMES C, Pinho R, Ponte A, Silva JC, et al
     Patient's perspective on the implementation of measures to contain the SARS-CoV-2 pandemic in a Portuguese Gastroenterology Department.
     Eur J Gastroenterol Hepatol. 2021;33:527-532.
     PubMed     Abstract available
     
     
     
124. TAMILARASAN AG, Krishnananthan T
     Faecal microbiota transplantation: what's beyond Clostridium difficile infection?
     Eur J Gastroenterol Hepatol. 2021;33:487-494.
     PubMed     Abstract available
     
     
     March 2021
125. CROOKS B, Misra R, Arebi N, Kok K, et al
     The dietary practices and beliefs of people living with older-onset inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2021 Mar 18. pii: 00042737-900000000-97269.
     PubMed     Abstract available
     
     
     
126. FERNANDES SR, Serrazina J, Rodrigues IC, Bernardo S, et al
     Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97288.
     PubMed     Abstract available
     
     
     
127. KARIYAWASAM VC, Mourad FH, Mitrev N, Paramsothy S, et al
     Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97273.
     PubMed     Abstract available
     
     
     
128. SCHARRER S, Kutschera M, Weseslindtner L, Primas C, et al
     Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2021;33:443-447.
     PubMed     Abstract available
     
     
     
129. CANCADO GGL, Nardelli MJ, Gouthier MAD
     Adalimumab-induced leukocytoclastic vasculitis in a Crohn's disease patient.
     Eur J Gastroenterol Hepatol. 2021;33:453.
     PubMed    
     
     
     
130. SHARMA V, Verma S, Kumar-M P, Mandavdhare HS, et al
     Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn's disease in patients started on antitubercular therapy.
     Eur J Gastroenterol Hepatol. 2021;33:334-338.
     PubMed     Abstract available
     
     
     February 2021
131. KYRIAKOS N, Papaefthymiou A, Giakoumis M, Galanopoulos M, et al
     Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center.
     Eur J Gastroenterol Hepatol. 2021 Feb 26. pii: 00042737-900000000-97290.
     PubMed     Abstract available
     
     
     
132. LOVERO R, Losurdo G, La Fortezza RF, Terracciano F, et al
     Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2021;32:201-207.
     PubMed     Abstract available
     
     
     
133. MANTAKA A, Tsoukali E, Fragaki M, Karmiris K, et al
     Reply to the letter to the Editor: 'The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease'.
     Eur J Gastroenterol Hepatol. 2021;32:300-302.
     PubMed    
     
     
     January 2021
134. KOUMAKI D, Machaira A, Katoulis AC, Bitados P, et al
     Mucocutaneous manifestations in patients with inflammatory bowel disease: a decade study from a Greek cohort.
     Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97312.
     PubMed     Abstract available
     
     
     
135. UNAL NG, Oruc N, Tomey O, Omer Ozutemiz A, et al
     Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission.
     Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97311.
     PubMed     Abstract available
     
     
     
136. MAGRI S, Chessa L, Demurtas M, Cabras F, et al
     Review article: safety of new biologic agents for inflammatory bowel disease in the liver.
     Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97310.
     PubMed     Abstract available
     
     
     
137. STRAATMIJER T, van Gennep S, Duijvestein M, Ponsioen CIJ, et al
     Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
     PubMed     Abstract available
     
     
     
138. FIGUEREDO CM, Nunes JGR, Mello-Neto JM, Carvalho AT, et al
     Higher salivary expression of S100A12 in patients with ulcerative colitis and chronic periodontitis.
     Eur J Gastroenterol Hepatol. 2021;33:116-117.
     PubMed    
     
     
     November 2020
139. WEISLINGER L, Guillo L, D'Amico F, Danese S, et al
     Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002008.
     PubMed     Abstract available
     
     
     
140. LYUTAKOV I, Lozanov V, Sugareva P, Valkov H, et al
     Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1097/MEG.0000000000001925.
     PubMed     Abstract available
     
     
     
141. LYU L, Chen D, Yu M, Yang Y, et al
     The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2020;32:1480-1481.
     PubMed    
     
     
     October 2020
142. GILISSEN LPL, Tajzai R, Romberg M, Pierik M, et al
     The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
     Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001980.
     PubMed     Abstract available
     
     
     
143. ROMEO S, Neri B, Mossa M, Calabrese E, et al
     Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease.
     Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001966.
     PubMed     Abstract available
     
     
     
144. KJAERGAARD S, Jensen TSR, Feddersen UR, Bindslev N, et al
     Decreased number of colonic tuft cells in quiescent ulcerative colitis patients.
     Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001959.
     PubMed     Abstract available
     
     
     
145. MOOSVI Z, Duong J, Bechtold ML, Nguyen DL, et al
     Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
     Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001944.
     PubMed     Abstract available
     
     
     
146. BHAMBHVANI HP, Zamora A
     Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001952.
     PubMed     Abstract available
     
     
     September 2020
147. LOPETUSO LR, Corbi M, Scaldaferri F, Petito V, et al
     Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment.
     Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001933.
     PubMed     Abstract available
     
     
     
148. VELLOPOULOU K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, et al
     Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece.
     Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001916.
     PubMed     Abstract available
     
     
     May 2020
149. OZKAN E, Basaranoglu M
     Recurrent 'gloves and socks' distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn's disease.
     Eur J Gastroenterol Hepatol. 2020;32:666-667.
     PubMed    
     
     
     April 2020
150. GUNEY M, Basaranoglu M
     A patient with Crohn's disease during remission by biological agent treatment developed active pulmonary tuberculosis and determining the eating habits.
     Eur J Gastroenterol Hepatol. 2020;32:541-542.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.